{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:14:02Z","timestamp":1777590842503,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The long-term postoperative occlusion of venous or arterial grafts following coronary artery bypass graft surgery (CABG) is a constant and unresolved problem, with a negative impact on clinical outcome. In our study, we aimed to find predictors that influence graft patency. The data of 202 patients who underwent CABG and had control coronary angiography on an average of 8.55\u2009\u00b1\u20094.56\u00a0years were analyzed retrospectively. Based on the presence of graft occlusion ascertained at control coronary angiography, patients were divided into two groups: 81 in the graft occlusion group (with 89 grafts degeneration: 64 saphenous vein [SVG] and 25 arterial graft) and 121 in the control group with patent grafts. The two groups were considerably well-matched regarding patient characteristics. Among medical conditions, peripheral artery disease has been found to be an independent predictor of increased graft occlusion, but only in SVG patients (OR 3.64, CI 1.21\u201311.03,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.021). When evaluating medical therapy, significantly more patients were on nebivolol in the control group, compared to the graft occlusion group (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.032). Moreover, nebivolol has been found to be an independent predictor of a lower degree of graft occlusion development (OR 0.36, CI 0.14\u20130.94,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.036). Nebivolol has been found especially effective in preventing SVG graft occlusion (OR 0.24, CI 0.07\u20130.76,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.015). Nebivolol has been found to reduce the frequency of graft occlusion following CABG, especially in case of SVG grafts. The vasodilatory properties of nebivolol may, at least in part, be responsible for the favorable effects of the drug to prevent graft occlusion.\n                  <\/jats:p>","DOI":"10.1007\/s11357-025-01688-5","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T21:58:10Z","timestamp":1746827890000},"page":"6885-6893","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Predictors of graft patency following coronary artery bypass graft surgery: the role of nebivolol therapy"],"prefix":"10.1007","volume":"47","author":[{"given":"T\u00edmea","family":"Balla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Maros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e1bor","family":"Csat\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00f3ra","family":"Erdei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrix","family":"V\u00e1nyai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel Johny","family":"Nellamkuzhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riko","family":"Shima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00e1niel","family":"Czuriga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Csan\u00e1di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Moln\u00e1r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u00f3ra","family":"Homor\u00f3di","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"K\u0151szegi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attila","family":"Kiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istv\u00e1n","family":"\u00c9des","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9880-0425","authenticated-orcid":false,"given":"G\u00e1bor Tam\u00e1s","family":"Szab\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"1688_CR1","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","volume":"139","author":"EJ Benjamin","year":"2019","unstructured":"Benjamin EJ, Muntner P, Virani SS, et al. Heart disease and stroke statistics-2019 Update: a report from the American Heart Association. Circulation. 2019;139:e56-528.","journal-title":"Circulation"},{"issue":"145","key":"1688_CR2","first-page":"e18","volume":"2022","author":"SJ Lawton","year":"2021","unstructured":"Lawton SJ, Committee W. ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;2022(145):e18\u2013114.","journal-title":"Circulation"},{"issue":"2","key":"1688_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","volume":"40","author":"F-J Neumann","year":"2019","unstructured":"Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. 2018 ESC\/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87\u2013165.","journal-title":"Eur Heart J"},{"issue":"3","key":"1688_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/eurheartj\/ehy856","volume":"40","author":"K Thygesen","year":"2019","unstructured":"Thygesen K. \u2018Ten Commandments\u2019 for the fourth universal definition of myocardial infarction 2018. Eur Heart J. 2019;40(3):226.","journal-title":"Eur Heart J"},{"issue":"2","key":"1688_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119\u201377.","journal-title":"Eur Heart J"},{"issue":"14","key":"1688_CR6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"J-P Collet","year":"2021","unstructured":"Collet J-P, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367.","journal-title":"Eur Heart J"},{"issue":"4","key":"1688_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1177\/1357633X18814335","volume":"26","author":"G Papai","year":"2020","unstructured":"Papai G, Csato G, Racz I, Szabo G, Barany T, Racz A, et al. The transtelephonic electrocardiogram-based triage is an independent predictor of decreased hospital mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. J Telemed Telecare. 2020;26(4):216\u201322.","journal-title":"J Telemed Telecare"},{"key":"1688_CR8","doi-asserted-by":"publisher","unstructured":"Szab\u00f3 GT, \u00c1goston A, Csat\u00f3 G, R\u00e1cz I, B\u00e1r\u00e1ny T, Uzonyi G et al. Predictors of hospital mortality in patients with acute coronary syndrome complicated by cardiogenic shock. Sensors (Basel) 2021; 21(3). https:\/\/doi.org\/10.3390\/s21030969.","DOI":"10.3390\/s21030969"},{"issue":"5","key":"1688_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1586\/14779072.2016.1154788","volume":"14","author":"ME Afari","year":"2016","unstructured":"Afari ME, Bhat T. Neutrophil to lymphocyte ratio (NLR) and cardiovascular diseases: an update. Expert Rev Cardiovasc Ther. 2016;14(5):573\u20137.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"12","key":"1688_CR10","doi-asserted-by":"publisher","first-page":"4907","DOI":"10.1177\/0300060518792445","volume":"46","author":"J Gao","year":"2018","unstructured":"Gao J, Liu Y, Li Y-M. Review of risk factors, treatment, and prevention of saphenous vein graft disease after coronary artery bypass grafting. J Intern Med Res. 2018;46(12):4907\u201319.","journal-title":"J Intern Med Res"},{"key":"1688_CR11","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1016\/j.jacc.2004.08.064","volume":"44","author":"S Goldman","year":"2004","unstructured":"Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a department of veteran\u2019s affairs cooperative study. J Am Coil Cardiol. 2004;44:2149\u201356.","journal-title":"J Am Coil Cardiol"},{"key":"1688_CR12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/0735-1097(96)00206-9","volume":"28","author":"GM Fitzgibbon","year":"1996","unstructured":"Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol. 1996;28:616\u201326.","journal-title":"J Am Coll Cardiol"},{"key":"1688_CR13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.coph.2012.02.012","volume":"12","author":"D Wiedemann","year":"2012","unstructured":"Wiedemann D, Kocher A, Bonaros N, et al. Perivascular administration of drugs and genes as a means of reducing vein graft failure. Curr Opin Pharmacol. 2012;12:203\u201316.","journal-title":"Curr Opin Pharmacol"},{"key":"1688_CR14","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/ejcts\/ezv268","volume":"49","author":"AC Deppe","year":"2016","unstructured":"Deppe AC, Arbash W, Kuhn EW, et al. Current evidence of coronary artery bypass grafting off-pump versus on-pump: a systematic review with meta-analysis of over 16,900 patients investigated in randomized controlled trials. Eur J Cardiothorac Surg. 2016;49:1031\u201341.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1688_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.4161\/oxim.3.3.11757","volume":"3","author":"AD Muir","year":"2010","unstructured":"Muir AD, McKeown PP, Bayraktutan U. Role of gender, smoking profile, hypertension, and diabetes on saphenous vein and internal mammary artery endothelial relaxation in patients with coronary artery bypass grafting. Oxid Med Cell Longev. 2010;3:199\u2013205.","journal-title":"Oxid Med Cell Longev"},{"key":"1688_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/1749-8090-8-172","volume":"8","author":"K Jerzewski","year":"2013","unstructured":"Jerzewski K, Ruel M, Voisine P, et al. Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery: exploratory analysis from the CASCADE trial. J Cardiothorac Surg. 2013;8:172.","journal-title":"J Cardiothorac Surg"},{"key":"1688_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3909\/ricm0663","volume":"14","author":"D Runyan","year":"2013","unstructured":"Runyan D, Gorges R, Feldman D, et al. Long-term follow-up of lesion-specific outcomes comparing drug-eluting stents and bare metal stents in diseased saphenous vein grafts. Rev Cardiovasc Med. 2013;14:1\u20136.","journal-title":"Rev Cardiovasc Med"},{"key":"1688_CR18","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.athoracsur.2011.04.107","volume":"92","author":"A Kulik","year":"2011","unstructured":"Kulik A, Voisine P, Mathieu P, et al. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial. Ann Thorac Surg. 2011;92:1284\u201390.","journal-title":"Ann Thorac Surg"},{"key":"1688_CR19","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1001\/jama.2018.3197","volume":"319","author":"Q Zhao","year":"2018","unstructured":"Zhao Q, Zhu Y, Xu Z, et al. Effect of ticagrelor plus aspirin, ticagrelor alone, or aspirin alone on saphenous vein graft patency 1 year after coronary artery bypass grafting: a randomized clinical trial. JAMA. 2018;319:1677\u201386.","journal-title":"JAMA"},{"key":"1688_CR20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/eurheartj\/ehae654","volume":"46","author":"S Sandner","year":"2025","unstructured":"Sandner S, Antoniades C, Caliskan E, et al. Intra-operative and post-operative management of conduits for coronary artery bypass grafting: a clinical consensus statement of the European Society of Cardiology Working Group on Cardiovascular Surgery and the European Association for Cardio-Thoracic Surgery Coronary Task Force. Eur Heart J. 2025;46:19\u201334.","journal-title":"Eur Heart J"},{"key":"1688_CR21","doi-asserted-by":"publisher","first-page":"633","DOI":"10.2165\/00003495-199957040-00011","volume":"57","author":"W McNeely","year":"1999","unstructured":"McNeely W, Goa KL. Nebivolol in the management of essential hypertension. Drugs. 1999;57:633\u201351.","journal-title":"Drugs"},{"key":"1688_CR22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/j.1365-2125.1994.tb04342.x","volume":"38","author":"AJ Bowman","year":"1994","unstructured":"Bowman AJ, Chen CPLH, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol. 1994;38:199\u2013204.","journal-title":"Br J Clin Pharmacol"},{"key":"1688_CR23","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1038\/sj.bjp.0703992","volume":"132","author":"C Maack","year":"2001","unstructured":"Maack C, Tyroller S, Schnabel P, et al. Characterization of \u00df1-selectivity, adrenoceptor-Gs-protein interaction and inverse agonism of nebivolol in human myocardium. Br J Pharmacol. 2001;132:1817\u201326.","journal-title":"Br J Pharmacol"},{"key":"1688_CR24","doi-asserted-by":"crossref","unstructured":"Bundkirchen A, Brixius K, B\u00f6lck B, Nguyen Q, Schwinger RHG. \u00df1-adrenoreceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies. Eur J Pharmacol. 2003;460:19\u201326.","DOI":"10.1016\/S0014-2999(02)02875-3"},{"key":"1688_CR25","doi-asserted-by":"publisher","unstructured":"Bayar E, Ilhan G, Furat C, Atik C et al. The effect of different beta-blockers on vascular graft nitric oxide levels: comparison of nebivolol versus metoprolol. https:\/\/doi.org\/10.1016\/j.ejvs.2013.11.003.","DOI":"10.1016\/j.ejvs.2013.11.003"},{"issue":"4","key":"1688_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1177\/0267659113517921","volume":"29","author":"S Sarikaya","year":"2014","unstructured":"Sarikaya S, Onk A, Boztosun B, et al. The effect of nebivolol on internal mammary artery blood flow during coronary artery bypass graft surgery. Perfusion. 2014;29(4):315\u201320.","journal-title":"Perfusion"},{"key":"1688_CR27","doi-asserted-by":"crossref","unstructured":"Kiss A, Szabo PJ, Dostal C et al. Specific graft treatment solution enhances vascular endothelial function. Rev. Cardiovasc. Med. 2022\u037e23(11):368\u2013377.","DOI":"10.31083\/j.rcm2311368"},{"key":"1688_CR28","doi-asserted-by":"crossref","unstructured":"Ritter JM. Nebivolol: endothelium-mediated vasodilating effect J. Cardiovasc. Pharm. 2001;38(Suppl. 3):S13\u2013S16.","DOI":"10.1097\/00005344-200112003-00003"},{"key":"1688_CR29","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/01.CIR.102.6.677","volume":"102","author":"MAW Broeders","year":"2000","unstructured":"Broeders MAW, Doevendans PA, Bekkers B, et al. Nebivolol: a third-generation \u00df-blocker that augments vascular nitric oxide release. Circulation. 2000;102:677\u201384.","journal-title":"Circulation"},{"key":"1688_CR30","doi-asserted-by":"publisher","unstructured":"Csato G, Erdei N, Vanyai B et al. Predictors of restenosis following percutaneous coronary stent implantation: the role of trimetazidine therapy. Front Cardvasc Med. 2022. https:\/\/doi.org\/10.3389\/fcvm.2022.873899.","DOI":"10.3389\/fcvm.2022.873899"},{"key":"1688_CR31","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.thromres.2019.03.016","volume":"178","author":"I Mazin","year":"2019","unstructured":"Mazin I, Paul G, Asher E. Neoatherosclerosis\u2014from basic concept to clinical implication. Thromb Res. 2019;178:12\u20136.","journal-title":"Thromb Res"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01688-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-025-01688-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-025-01688-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T04:42:20Z","timestamp":1763700140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-025-01688-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,10]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1688"],"URL":"https:\/\/doi.org\/10.1007\/s11357-025-01688-5","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,10]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures were carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}},{"value":"Not relevant to this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}